Table III.

Demographics and outcome measures for high nephrotoxic medication exposure and AKI rate in the NICU

Demographics	Pre-NINJA era	NINJA initiation era	NINJA sustainability era	P value*	P value†	Pvalue‡
Gestational age at birth ($\overline{\text{x}}$ ± SD)	31.2 ± 6.4	31.3 ± 6.6	32.2 ± 6.3	.118	1.305	1.339
Gestational age at exposure ($\overline{\text{x}}$ ± SD)	40.3 ± 10.4	39.1 ± 11.3	39.8 ± 9.2	.841	.650	.442
Age of exposure, d ($\overline{\text{x}}$ ± SD)	62.8 ± 73.4	57.9 ± 117.2	53.9 ± 75.5	.372	.400	1.007
Outcome Measures
SCr compliance	56.5%	90.7%	86.0%	<.001	.950	<.001
High nephrotoxic medication exposure prevalence rate (per 1000 patient-d)	12.4	16.4	9.6	.034	<.001	.030
AKI prevalence rate (per 1000 patient-d)	3.1	5.1	1.1	.055	<.001	<.001
Rate of patients with high nephrotoxic medication exposure who develop AKI (%)	25.2	30.9	11.0	.339	<.001	<.001
AKI intensity rate (per 100 susceptible patient-d)	6.0	9.1	2.9	.010	<.001	<.001

Simple t test for continuous variables, all other statistics performed with Poisson regression analysis with exception of χ² for % of high nephrotoxic medication exposure who develop AKI.

^*Pre-NINJA era vs NINJA initiation era.

^†NINJA initiation era vs NINJA sustainability era.

^‡Pre-NINJA era vs NINJA sustainability era.